Clinical trial · Observational
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to analyze cases of human epidermal growth factor receptor (HER) 2-positive metastatic breast cancer (MBC) of the last 10 years at the University Hospital of Zurich to assess the efficacy of the treatment with trastuzumab in HER2-positive MBC and to find out associations between different variables and the outcome. The aim is to find out probable prognostic factors and patterns of disease progression. Prognostic factors could optimize treatment approaches and result in a delay of disease progression.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| ERBB2 | — | UNRESOLVED | — |
| Metastatic Neoplasm | Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- HER2+ metastatic breast cancer
- interventionNames
- Other: observation
Primary outcomes (1)
- measure
- Time to disease progression
- timeFrame
- up to 120 months
- description
- time from commencing trastuzumab (or other anti-HER2 therapy) to the time of disease progression or death
Secondary outcomes (1)
- measure
- Response duration
- timeFrame
- up to 120 months
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Received at least 1 dose of trastuzumab in metastatic setting at the University hospital of Zurich from 01/2004 to 12/2014. * HER2+ status confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) ≥ 2. Exclusion Criteria: \-
References
Publications (0)
Data not yet available